toxicokinetics

Oncology

Successfully navigating the process for drugs with a higher risk-benefit ratio requires a tailored non-clinical programme design.

News

Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.